Please find attached investor presentation for Q1FY27

July 30, 2026 BSE Limited National Stock Exchange of India Limited P J Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543904 Symbol: MANKIND Dear Sir/ Madam, Subject: Investor Presentation Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Please find enclosed herewith the investor presentation on financial results of the Company for the quarter ended on June 30, 2026. The presentation is also being uploaded on the website of the company i.e. www.mankindpharma.com. You are requested to kindly take the above information on your records. Thanking You, Yours Faithfully, For Mankind Pharma Limited Hitesh Kumar Jain Company Secretary & Compliance Officer Encl.: A/a Q1 FY27 July 2026 Index 03 Additional Information • Mankind Pharma at a Glance (FY26) • Key Milestones • Expansion in Specialty and Super Specialty Segments 01 Financial Performance • Financials - Steady Growth Trajectory • Key Financials – Q1 FY27 • Shareholding Pattern • P & L Highlights – Q1 FY27 • Annexures • Key Financial Metrics – Q1 FY27 • Q1 FY27 Earnings Call Details 02 Business Updates – Q1 FY27 • Domestic Business (ex-CH) • Consumer Healthcare Business (CH) • Export Business Mr. Rajeev Juneja Vice Chairman & Managing Director Segmental Revenue Break - Up • Revenue grew~13%YoY with EBITDA margins improving by 250 bps to 26.3% • Overalldomestic business (ex CH) grewby 11.0% led by:  Double digit growth in Mankind domestic business with 15.8% growth in 15% 7% Chronic – 19.4% in cardiacand 12.7% in anti-diabetes  Outperformance in Gastro, VMN, Gynaec led to growth recoveryin acute  Strong double digit growth in BSV domestic specialty business 3,426 4,031 • OTCsegment grewby ~4%; while International business grew29% • Our disciplined execution and strengthening business fundamentals, resulted Domestic Business (Ex CH) in improvements across key operating and financial metrics in Q1FY27, laying the foundation to deliver long-term sustainable growth Consumer Healthcare (CH) Domestic Exports 1. On TTM Basis, Adj. ROCE excludes BSV Acquisition || 2. Calculated on TTM EBITDA adjusted with one time impact of labourcode regulations and other non-recurring cost 4 INR Cr Q1 FY27 Q1FY26 YoY Growth Q4FY26 QoQ Growth Revenue from Operations (A=B+C) 4,031 3,570 12.9% 3,443 17.1% Domestic Business (B) 3,426 3,101 10.5% 2,886 18.7% i. Domestic Business (ex CH) 3,180 2,864 11.0% 2,673 19.0% ii. Consumer Healthcare (CH) 246 237 3.9% 213 15.5% Exports Business (C) 605 469 29.0% 557 8.5% Gross Profit 2,932 2,517 16.5% 2,485 18.0% EBITDA 1,060 850 24.7% 910 16.5% Profit After Tax 574 445 29.1% 559 2.6% Diluted EPS1 (INR) 13.7 10.6 29.6% 13.4 2.5% Cash EPS1 (INR) 19.2 15.9 20.8% 19.1 0.4% Gross Margins % 72.8% 70.5% 230 bps 72.2% 60 bps EBITDA Margins % 26.3% 23.8% 250 bps 26.4% 10 bps Adjusted EBITDA Margins % 26.3% 23.8% 250 bps 27.1%2 80 bps PAT Margins % 14.2% 12.5% 170 bps 16.2% 200 bps 1. Diluted EPS and Cash EPS not annualised|| 2. Adjusted with one time impact of labourcode regulations 5 Cash Flow from Operations (INR Cr) CAPEX (INR Cr) ROCE2 EC BF IO TD to A 80% 89% 99% 77% CA oP fE RX e a vs % 4.3% 5.2% 3.6% 4.9% With BSV With BSV With BSV With BSV Acquisition Acquisition Acquisition Acquisition 723 263 40% 41% 42% 43% 814 761 187 460 91 593 128 163 840 840 817 198 546 125 127 127 11%* 12% 11%* 13% FY25 FY26 Q1FY26 Q1FY27 FY25 FY26 Q1FY26 Q1FY27 Mar31, Mar31, Jun30, Jun30, Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2025 2026 2025 2026 Net Cash / (Net Debt) (INR Cr) Net Operating Working Capital Days2 Net-Debt 1.6x 1.4x 1.3x 1.1x 0.9x With BSV With BSV With BSV With BSV to EBITDA3 Acquisition Acquisition Acquisition Acquisition 50* 52 52 45 43 44 44 (3,377) (3,932) (4,294) (4,791) (5,249) Mar31, Mar31, Jun30, Jun30, Jun30, Sep30, Dec31, Mar31 Jun30, 2025 2026 2025 2026 2025 2025 2025 2026 2026 1.Above FY25 P&L items are for continuing operations only || 2. On TTM Basis || 3. calculated on Adj. EBITDA basis | *Includes BSV from 23-Oct-2024 || Refer Annexure for Formulas 6 Strong Growth in Domestic (ex-CH) Revenue1,2 INR Cr 11,338 9,866 8,741 7,761 2,864 3,180 FY23 FY24 FY25 FY26 Q1FY26 Q1FY27 Domestic revenue (ex- CH) increased 11.0% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business Secondary sales3 growth of 12.7% vs 13.0% IPM4 in Q1FY27 – primarily due to  strong performance3 in chronic growth supported by 19.4% in Cardiac and 12.7% in Anti-Diabetes  outperformance3 in Gastro (1.2x), VMN (1.2x), Gynaec (1.05x) led to growth recovery in acute, also recovery seen in anti-infectives (3.6% in Q1FY27 vs -1.1% in Q4FY26) Strong growth in key focused brands:  outperformance in key acute brands3 like Cefakind-CV (1.2x), Nurokind-LC (1.1x), Pantakind (1.8x), Dydroboon (1.5x) etc in Q1FY27  21% growth in Telmikind family; 30%/31% in Lipirose / Statpure in cardiac during Q1FY273  Glizid brand family grew 29%YoY in Q1FY273 Healthy growth in BSVs key brands3 - Foligraf (39%), Humog (39%) and Anti-D (23%) Consistently maintained #1 rank over last 9 years with prescription share of 15.2%3 1.FY24 and FY25 P&L items are for continuing operations only and hence FY23 numbers are strictly not comparable || 2. Denotes Reported Number including BSV w.e.f23-Oct-2024 || 3.As per IQVIA Jun 2026 || 4. Ex-Trizepatide Consistent focus to increase chronic contribution Overall Chronic Growth 1.4x 1.2x 1.1x2 1.4x2 1.0x2 41.2 40.4 40.0 39.6 38.3 39.0 38.5 38.8 14.7 16.8 15.8 13.5 13.6 13.4 11.9 36.6 10.7 9.7 9.8 35.2 FY24 FY25 FY26 Q1FY26 Q1FY27 FY24 FY25 FY26 Q1FY26 Q1FY27 IPM Chronic Share % Mankind Chronic Share % IPM Chronic Growth % Mankind Chronic Growth % Mankind Consolidated Chronic Share 1.1x outperformance to IPM both in Cardiac and Anti-Diabetic2 respectively in Q1FY27 1.3x outperformance to IPM in Respiratory Chronic in Q1FY27 38.3 39.0 40.4 37.0 40.0 36.8 41.2 38.0 34.0 35.4 Consistent outperformance across key portfolio supported by key strategic launches  23% combined YoY growth in inhaler (Combihale & Symbicort)  45% YoY growth in Nobeglar (Insulin Glargine) FY24 FY25 FY26 Q1FY26 Q1FY27 IPM Chronic Share % Mankind Chronic Share % As per IQVIA JUN-26 || 1. Mankind excluding BSV || 2. Ex-Trizepatide 9 High Ranks across Acute and Chronic Areas FY26 - Sales Mix representing Diversified Therapy Presence Rank in CVM MS% FY 21-26 CAGR Key Therapy Areas (FY26) (FY26) Mankind1 IPM 2% Chronic therapies 3 4.3% 14.3% 11.4% Cardiovascular Anti-Infectives Cardiovascular 4 5.5% 17.3% 11.1% 4% Gynaecology Gastro Intestinal Anti Diabetic 4 4.5% 12.1% 8.2% 4% Anti Diabetic VMN Acute therapies 2 5.0% 11.4% 9.6% 11% Respiratory Urology Anti-Infectives 5 6.0% 12.2% 10.3% Dermatology Pain / Analgesics Gynaecology 1 10.3% 23.2% 10.1% 6% Neuro / CNS Others Gastro Int 6 4.3% 8.7% 10.5% 11% Respiratory 6 4.5% 13.9% 12.7% VMN 2 5.1% 7.8% 9.1% Overall 2 4.7% 12.4% 10.3% Q1FY27 – Key Therapies Performance 19.4% 19.3% 16.9% 17.3% 16.3% 13.5% 12.7% 12.1% 12.7% 11.1% 13.6% 12.7% 11.3% 10.6% 13.0%2 8.5% 11.1%2 3.6% Overall Cardio Anti Gynae Gastro Int Anti VMN Respiratory vascular Infectives Diabetic IPM Growth Rate % Mankind Growth Rate % As per IQVIA Jun-26 || 1. Includes BSV from Oct-2024 || 2. Ex-Trizepatide 10 Consumer Healthcare Segment Revenue (INR Cr) EBITDA % 19.9% 19.0% 18.7%1 18.0% 18.6% 692 706 237 246 FY23 FY24 FY25 FY26 Q1FY26 Q1FY27 Revenue growth of 4% YoY in Q1FY27 partly impacted by base effect of discontinued cash and carry business Despite softer growth, we gained market share2 in key Brands – Manforce, Preganews and Gas-o-fast MT & E-Com share increased to 15% in Q1FY27 as compared to 11% in Q1FY26 supported by 38% growth Healthy growth in secondary sales2 for Gas-o-fast and Ova news of 10% and 36% YoY respectively in Q1FY27 1. Denotes EBITDA adjusted with one time labour code impact, reporte [Showing first 8,000 characters — download PDF for full document]